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Abstract
Background: The current review analyzes the long-term outcome and prognosis of early onset schizophrenia
based on previously published studies in 1980.
Methods: A systematic search of articles published in the English-language literature after 1980 identified a total of
21 studies, which included 716 patients who were either suffering from early onset schizophrenia (EOS) or both
EOS and other psychotic disorders (MIX). The authors of the current review scored the outcome as either “good,”
“moderate,” or “poor.” The mean age of onset in these studies was <18 years.
Results: In general, the outcome in studies with EOS is worse than the outcome in MIX studies. Only 15.4% of the
patients in EOS studies versus 19.6% of the patients in MIX studies experienced a “good” outcome. In contrast,
24.5% of the patients in EOS studies versus 33.6% in MIX studies experienced a “moderate” outcome, and 60.1% in
EOS studies versus 46.8% in MIX studies experienced a “poor” outcome. The authors identified various significant
effects on outcome. In EOS, the findings were significantly affected by sample attrition, indicating that in studies
with a high dropout rate, fewer patients experienced a “moderate” outcome, and more patients experienced a
“poor” outcome; however, the effect sizes were small. Furthermore, the effects were also small and more favourable
for specific functioning measures, as opposed to more global measures, small to moderate in terms of worse
outcomes for follow-up periods >10 years, small to moderate for more unfavourable outcomes in males, and small
to large for worse outcomes in studies including patients diagnosed before 1970.
Conclusions: In contrast to the adult manifestation, the early manifestation of schizophrenia in childhood and
adolescence still carries a particularly poor prognosis. According to these aggregated data analyses, longer
follow-up periods, male sex, and patients having been diagnosed before 1970 contribute predominantly to the
rather poor course of EOS.
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Background
Traditionally, schizophrenia has been perceived as a dis-
order with high rates of chronicity and deterioration
over time. Some recent studies have shown better prog-
nosis of the disorder [1,2]. Typically, the onset is in early
adulthood with less frequent manifestation in adoles-
cence and rare onset in childhood. In the literature, the
definition of early onset schizophrenia (EOS), or
adolescent onset schizophrenia, varies with studies de-
fining it as onset before age 17–21 [1,3-18].
Quite similarly, the age of onset in very early onset
schizophrenia (VEOS), or childhood onset schizophrenia
(COS) also varies across studies with definitions before
12–15 years of age [3,9,15,17,19-25]. The most common
definition of EOS is onset before age 18, and the most
common definition of VEOS is onset before age 13.
While adult onset schizophrenia (AOS) has been stud-
ied in great detail for many decades, research on EOS
and VEOS is still more limited, partly due to its low
prevalence and the fact that EOS was not recognized in
the diagnostic systems before the introduction of DSM-
III. The prevalence of schizophrenia in children and
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adolescents is rather low, with estimates of VEOS vary-
ing between 1 in 10.000 [21], 1 in 30.000 in children be-
fore age 13 [13], and 1.4 in 10.000 before age 15 [26].
Among patients with schizophrenia, a Finnish study
found that 4.7% had onset at or before age 18 [27].
The nosological status of schizophrenia in children has
been discussed for many years. In the DSM-II, the cat-
egory of childhood schizophrenia referred to both psych-
otic and autistic disorders; however, the eminent studies
by Kolvin et al. [28] made clear that schizophrenia in
children had to be differentiated from autistic disorders.
Since the appearance of the DSM-III, children with
schizophrenia have been diagnosed with the same cri-
teria as adults [23,29-31]. Both the stability and reliabil-
ity of the diagnosis of EOS [31-35] as well as the validity
of the diagnosis in children and adolescents are firmly
established [1,36-39].
In 2005, more than 800 studies focused on the out-
come of schizophrenia, irrespective of age at onset [40];
however, the majority looked at adult onset. Most stud-
ies on outcome of EOS have been restricted to small
samples and/or short follow-up periods. The results are
inconclusive across studies with some showing a prog-
nosis resembling that of AOS but most reporting poorer
prognosis [21,23,34,38,41]; only a few studies do not
concur with this trend [42-44].
One of the more recent cohorts was studied at the
Early Psychosis Prevention and Intervention Centre
(EPPIC) in Melbourne, Australia [45]. This cohort con-
tained patients with mixed early and adult onset psych-
osis. At a rather short mean follow-up of 18 months, the
study found no significant difference between early and
adult onset on outcome variables related to remission. In
a more recent analysis, the follow-up period in the EOS
subsample was extended to a mean of 6.9 years; the
authors claimed that there was a better outcome in the
EOS group compared to the adult onset group [42].
It has been suggested that differences in outcome
across studies may be more to the degree of disability
than in the rate of recovery [30]. Generally, there is
agreement that the course of schizophrenia is rather het-
erogeneous among both adults and children [41,46,47].
Various predictors of outcome have been studied with
no clear picture emerging due to a lack of replication
studies. However, there is evidence that the diagnosis of
VEOS predicts lower educational achievement, less inde-
pendence both economically and emotionally, lower
rates of employment, poor social relationships, and a
continuing need of psychiatric care [21].
The current systematic review is focused on the ana-
lysis of the entire existing literature on the long-term
outcome of EOS published since 1980 in English-
96 full text articles assessed for eligibility
646 results screened
646 records after duplicates (334) were 
removed
40 additional records identified through 
other sources
455 records identified through Psycinfo/ Psycarticles
485 records identified through Pubmed
50 studies included in qualitative synthesis
46 full text articles excluded due to: 
- No schizophrenia in sample. 
- Mean age >18
- Follow-up <1 year
- Case-reports 
- No follow-up
- Only mean outcome scores
- No functional outcome scores.
444 excluded based on title
106 excluded based on abstract
21 studies included in 
quantitative synthesis
Figure 1 Flowchart of the literature search.
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language journals. We have chosen not to include stud-
ies published before 1980 because, regardless of their
scientific validity at the time, they focused primarily on
symptoms, they did not report on functional outcome in
a standardized way, and they did not express shortcom-
ings in terms of the studies’ participants. In addition to
detailed descriptions, the current analysis is based on in-
ferential statistical tests of aggregated data across studies
in order to study both effects and prognostic factors.
The report was written in accordance with the guide-
lines of the PRISMA statement [48].
Methods
Identification of studies
The literature search was carried out using the following
databases: PsycINFO, Pubmed, and PSYCarticles. A
search in Psycinfo and PSYCarticles for English-language
articles published since 1980 using the criteria “AB=
adolescent onset schizophrenia,” OR “childhood onset
schizophrenia,” OR “very early onset schizophrenia,” OR
“early onset schizophrenia” yielded 455 results. A search
of publication titles and abstracts in PubMed based on
the same terms and limitations yielded a total of 485
articles; 96 articles were chosen for further inspection.
In addition, studies mentioned in previous review arti-
cles were also considered. The process of the literature
search is shown in Figure 1.
Due to the interest in performing quantitative analyses
based on inferential statistical tests, the following exclu-
sion criteria were used: single case studies, studies report-
ing only on single or specific parameters (e.g., IQ or
mortality) but no overall broad outcome measures allow-
ing a classification into “good,” “moderate,” or “poor” out-
come (see below), studies only reporting on mean
outcome parameters, studies not based on internationally
accepted diagnostic criteria (as reflected in the ICD and
the DSM), studies with follow-up time <1 year, and studies
with poor description of outcome criteria (e.g., no global
functioning scores). In the case of duplicate publishing,
data from the sample were included only once in the data
set with the study that included the latest selected assess-
ment. The analysis included both retrospective and pro-
spective studies.
A mean age of ≤18 years was required. The majority
of the studies only included patients aged <18 years with
just a few studies also including 18 year olds
[5,11,49,50], one study including patients aged 19 years
[6], and one study [32] including a few patients aged
20 years at the time of onset; however the latter study
was included because of a mean age at onset of
16.8 years. Studies reporting data on pure EOS and stud-
ies reporting combined data on EOS and other psychotic
illnesses (MIX) were included in the analyses.
A total number of 21 studies were suitable for analysis
[1,5,6,8,11,15,18,23,29,32,38-41,49-55].
Outcome measures and effect variables
All data was collected from published material only. The
studies were categorized as reporting outcome by use of
either a General Functioning Scale (GFS, including Glo-
bal Assessment of Functioning (GAF, [56])), Children`s
Global Assessment Scale (CGAS, [57]), and Global As-
sessment Scale (GAS, [58]) or Study-Specific Functioning
(SSF) outcomes. All GFS studies used scales running
from 0 to 100. A total of 10 studies used GFS scales
[5,23,32,39,40,50-53,55]. The GFS studies were categor-
ized as a “poor” outcome (score ≤ 50), “moderate” out-
come (score 51–70), or “good” outcome (score >70). Out
of these ten studies, five had deviating definitions of the
three outcome categories. As described in Table 1, four
studies used other cut-offs for “poor,” “moderate,” and
“good” [5,23,40,52]. One study [51] even divided the
more generally used class of “poor” outcome into dete-
riorated (< 30) and minimal improvement (30–50). These
two groups were combined into “poor” outcome (< 50),
whereas all other deviating ratings were taken directly
into the analysis.
The SSF outcomes were also rated as “poor,” “moder-
ate,” or “good” depending on the outcome as defined in
these studies and shown in Table 1. In two studies [6,29]
ratings were based on outcome scales, whereas the ratings
in the remaining nine studies [1,8,11,15,18,38,41,49,54]
were based on categorical outcome measures. Based on
the above-mentioned three categories of outcome and
using the same cut-off scores, the three authors of the
current study performed the ratings independently in each
study. There was full consensus among the three authors
in the independent ratings of 19 studies, and after two
authors agreed in the remaining two studies, full consen-
sus was also reached for these remaining two ratings.
Dropout rates were comprehensively described in 17
studies and ranged from a minimum of 0% [6,23,55] to a
maximum of 59% [15]. Reasons for dropout included
untraceable subjects, subjects refusing to participate,
death, moving out of the area, and suicide. One study,
however, included suicide as a measure of outcome [50],
but since most studies did not do so, suicides were sub-
tracted from the data in this particular case in order to
have consistent criteria for all ratings.
A total of five predicting variables were considered in
the analyses as to their effect on the outcome measures:
drop-out rate, type of measures of functioning, duration
of follow-up, sex, and time period when patients had been
diagnosed. Duration of follow-up was grouped into 1–10
and >10 years. The cut-off was chosen to obtain compar-
able sample sizes. If the duration of follow-up did not fit
into one of these two outcome groups due to varying
Clemmensen et al. BMC Psychiatry 2012, 12:150 Page 3 of 16
http://www.biomedcentral.com/1471-244X/12/150
Table 1 Overview of the 21 Studies
Sex Outcome (%)
Authors Diagnosis Period of
Diagnosis
N Dropout
N (%)
Age at
onset (yrs.)
Female Male Duration of
follow-up (yrs.)
Outcome criteria Original outcome
ratings
Good Moderate Poor
N (%) N (%)
Hassan et.al
(2011)
SZ, psychosis
NOS
2003-2010 37 14 (27) Mean = 12.2 23 (62) 14 (38) Mean =3.2 CGAS: Good: ≥ 70 27.0 48.7 24.3
Moderate 40-70
Poor: ≤ 40 and
partial or no
remission.
Ledda et al.
(2009)
SZ 1992-2002 15 2 (12) Mean = 15.1 9 (53)* 8 (47)* 5 GAF* 11.8 60.0 27.6
Reichert
et al. (2008)
SZ & SZ-AFF 1990-2000 27 59 (80) Mean = 15.5 8 (30) 19 (70) Mean= 13.4 Employment 3,7% university study 22.2 51.8 25.9
18,6% regular work
48,1 sheltered work
25,9% unable to work
3,7% unemployed
Remschmidt
et al. (2007)
SZ 1920-1961 38 0 (0) 5-14 23 (61) 15 (39) Mean= 42 GAS: 5.8 23.7 60.5
Good >71
Moderate: 41-70
Poor: <40
Fleischhaker
et al. (2005)
SZ 1983-1988 81 20 (20) 11-18 36 (44) 45 (56) 4-11 GAF: 19.80 38.20 42.00
Poor: <40
Moderate: 41-70
Good >71
Helgeland
et al. (2005)
SZ 1963-1978 9 N.A 13-17 1 (11) 8 (89) Mean= 28,1 Social disability
(medication,
means of income,
living situation)
All on antipsychotic
medication at
follow-up, all on
disablement benefits,
none living in an
ordinary home
0,00 0.0 100.00
Röpcke et al.
(2005)
SZ, SZ-AFF,
schizo-phreni-
form disorder
1979-1988 39 16 (29) Mean = 16 19 (49) 20 (51) 10.2-21.2 GAS: 21.00 28.00 51.00
Good >60
Moderate: 51-60
Poor: <51
Jarbin (2003a) SZ 1982-1993 30 58 (66) 11.8 - 18.7 11 (37) 19 (63) 5.1-18.2 GAF (or employment
if GAF not available)
79% very poor 3.00 0.00 97.00
18% poor
3% good
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Table 1 Overview of the 21 Studies (Continued)
Hollis, (2000b) SZ 1973-1991 51 17 (25) Mean = 14.0 22 (43) 29 (57) 4-22 Remission at
follow-up
12.00 40.00 48.00
Lay et al. (2000) SZ & SZ-AFF
(ICD-9)
1976-1987 65 31 (32) 11,5-17,9 38 (59) 27 (41) 10 Social disability
(DAS-scale and global
evaluation on a
6-points scale)
12,5% no
dysfunction,
20.00 44.00 36.00
7,8% minimum,
14,1% obvious,
29,7% serious,
31,3% very serious,
4,7% maximum
dysfunction
McClellan
et al. (1999)
SZ 11 7 (39) 11-16 3 (27) 8 (73) 2 Course of illness
and description
of impairment
0.0 9.00 91.00
Aarkrog (1999) SZ, SZ-AFF 1968-1976 28 N.A. 12-20
(M= 16.8)
7 (25) 21 (75) 17-26 GAS 3.6 17.9 78.5
Eggers et al.
(1997)
SZ (DSM-III-R) 1925-1961 44 27 (38) 6-14 25 (57) 19 (43) Mean= 42 Social disability
(Eggers social
scale)
1-2: Good remission
GAS >70
25.00 25.00 50.00
3-4: Moderate
remission <GAS 51
5-6: Poor
remission - < GAS 40
Maziade et al.
(1996)
SZ (DSM-III-R) 1968-1990 40 37 (48) 10-17 13 (33) 28 (67) 14.8 GAS 5.00 15.00 80.00
Werry et al.
(1994)
SZ, Schizo-
phreni-form
disorder
1968-1990 53 41 (36) 7-17 22 (42) 31 (58) 4.3 Living situation 20.7 17.00 62.30
Rund 1994 SZ (ICD-9) 1980-1990 24 0 (0) 13,1-17,9
(Mean= 16)
8 (33) 16 (67) 2 GAS 0 21.0 79.0
Cawthron
et al., 1994
SZ (ICD-9) 1975-1986 9 10 (53) 14-18 - - 2-13 Adult Personality
Functioning
Assessment
Seven (78%)
continuously ill.
None of these
employed or
married; extremely
poor social
functioning. The
two recovered
patients (22%)
were ill for only
2% of the follow-
up period.
22.00 0.00 78.00
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Table 1 Overview of the 21 Studies (Continued)
Asarnow et al.
(1994)
SZ 1980-? 18 3 (14) 6-11,3 5 (24) 13 (76) 2-7 CGAS 28% good
outcome
CGAS >60, 28%
28.00 28.00 44.00
>60 = good
51-60 =moderate moderate
improvement
CGAS 51–60, 28%
<51= poor
minimal
improvement
CGAS <51, 17%
deteriorating
CGAS <41
Gillberg et al.
(1993)
SZ (DSM-III /
ICD 9)
Born
1960–1982.
23 0 (0) 13-19 9 (39) 14 (61) 11-17 Overall register
data outcome
13% overall
possibly good
13.00 9.00 78.00
9% intermediate
outcome
78% extremely
poor
Krausz et al.
(1993)
SZ, mood
disorders,
psychoses (PSE)
1972-1978 55 6 (10) 14-18 28 (51) 27 (49) 11-16 Mental and social
handicaps rated
according to
Brown (1966),
20% inpatient, 26% 29.6 18.5 51.9
seriously
handicapped
16% handicapped
but employed
26% not
handicapped
12% no findings
Inoue et al.
(1986)
EOS and acute
psychotic
episode (DSM-III)
1971-1981 19 N.A. 10-17 9 (47) 10 (53) 3 Ability to work 47% unable
to work
16.00 37.00 47.00
16% limited
work ability
21% working
at a lower level
than previously,
16% working
as before
If not otherwise specified: GAF: Global Assessment of Functioning >70 =Good; 70-51 =Moderate; <51 = poor. SZ: Schizophrenia. SZ-AFF: Schizoaffective disorder. CGAS: Children Global Assesment of Functioning Scale.
GAS: Global Assessment Scale. N.A. = Not assessed. PSE = Present State Examination. *Based on N at baseline.
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length of follow-up within the sample, the mean duration
was used for classifying the study [5,38,49,51].
In one study, there was no information on sex distri-
bution [49], and only a minority of studies reported out-
comes stratified for sex [1,11,41,52]. Multiple studies
noted sex differences without reporting stratified data.
Time period of diagnosis considered studies including
patients diagnosed before and after 1970 (<1970+)
[1,6,18,23,29,32,49] and studies with all patients diagnosed
in 1970 and later (≥1970) [5,8,11,15,34,36,38,40,41,52,53,55].
Finally, diagnoses were considered by dividing the
data-set into studies containing only patients with EOS
and studies including both patients with schizophrenia
and patients with other psychotic disorders, i.e., psych-
osis (MIX).
Statistical analyses
The three categories of “good”, “moderate”, and “poor”
were calculated in percentages and rounded to the near-
est decimal. In order to take into account the large vari-
ation in sample sizes, weighted percentages were
calculated by weighting each reported rate with the size
of the study group. All analyses were based on adjusted
sample sizes at follow-up assessments rather than actual
sample sizes after patient recruitment.
Due to consistent and significant deviation of the data
from the normal distribution, non-parametric tests were
used in the analyses. The effects of the four predicting
variables mentioned above on the three outcome mea-
sures were analyzed using the Mann Whitney test with
Bonferroni adjustments of p-values correcting for mul-
tiple testing. Considering five tests, findings were signifi-
cant at the p = 0.01 level and highly significant at
p = 0.002. In addition, effect sizes were calculated using
the formula of rho = z/√N), where 0.1 is indicating a
small effect, 0.3 a moderate effect, and 0.5 a large effect.
Data analyses were performed by use of the SPSS 20
(SPSS, Chicago).
Results
Study characteristics
The current review is based on 21 studies containing
716 patients at follow-up. Detailed information on study
characteristics and outcome findings is provided in
Table 1. The sample sizes ranged from 9 to 81 patients
with a mean group size of 44.4 (SD= 19.4). There were
considerable differences in design, group size, methods,
duration of follow-up, type of evaluation, and missing
data. Diagnostic classification changed considerably over
the period in which the studies were conducted given
the fact that patients had been diagnosed over a wide
time period ranging from 1920 to 2010. Since the 1990s,
there has been an increasing reliance on DSM-IV and
ICD-10 criteria. In 16 studies consisting of 592 patients,
the mean age at onset was 14.9 (SD= 1.6) years; five
studies reported only age ranges [6,8,11,49,51].
The mean duration of follow-up varied between 1.5
and 42.0 years (mean = 14.4; SD= 11.4). In 20 studies
based on 707 patients, a total of 394 males (56.5%) were
included. Repeated follow-up assessments were based on
six samples and findings were described in nine articles
[8,11,29,35,41,53,54,59,60]. Unfortunately, the data from
these studies are not suited for repeated measurement
analysis because both the sample sizes between follow-
up periods (except [11]) and the duration of follow-up
differed considerably. The total group of studies (N= 21)
was divided into a group of EOS studies (N= 422) and a
group of MIX studies (N = 294).
Table 2 Outcome by diagnoses based on 21 studies (N=716)
Percentages of subjects by diagnosis
Outcome variable EOS Mixed Analysis
Mean SD Range Median Mean Rank Mean SD Range Median Mean Rank U z p rho
N=422 N=294
Good 15.4 7.7 0-28 15.8 300.05 19.6 9.1 0-29 21.0 442.40 37368 −9.08 <.001 0.34
Moderate 24.5 14.6 0-60 23.7 299.75 33.6 12.9 18-52 37.0 442.83 37241 −9.13 <.001 0.34
Poor 60.1 18.9 27-100 60.5 410.59 46.8 17.8 24-79 47.0 283.73 40051 −8.09 <.001 0.30
Table 3 Outcome by attrition rate based on 18 studies (N= 660)
Percentages of subjects by dropout rate
Outcome variable Low dropout (<28%) High dropout (>28%) Analysis
Mean SD Median Mean Rank Mean SD Median Mean Rank U z p rho
N=342 N=318
Good 18.8 8.2 19.8 324.72 17.0 8.0 20.7 340.77 52400.000 −1.081 n.s. 0.04
Moderate 32.0 12.8 38.2 370.67 25.2 15.6 25.0 291.96 42007.500 −5.301 <.001 0.21
Poor 49.1 15.3 48.0 293.44 57.7 21.3 51.0 373.99 41703.500 −5.423 <.001 0.21
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In addition to the various descriptive parameters,
Table 1 contains columns reporting the outcome criteria
used in the various studies, the original outcome ratings,
and the outcome (in%) divided into the three categories
of “good,” “moderate,” and “poor,” as calculated and
rated by the us, which we based on the data in the pre-
ceding column containing the original outcome ratings.
Outcome in samples of pure EOS vs. mixed psychotic
disorders
As shown in Table 2, studies only containing EOS
patients came up with a rate of 15.4% with a “good” out-
come, whereas 24.5% experienced a “moderate” out-
come, and 60.1% experienced a “poor” outcome. In the
MIX samples, the figures were 19.6% with “good” out-
come, whereas 33.6% experienced a “moderate” out-
come, and 46.8% experienced a “poor” outcome. In each
outcome category, though, the variation across studies
proved to be remarkably high.
There were significant differences in outcome between
the EOS and the MIX samples. A significantly greater
proportion of the MIX samples experienced a “good” or
“moderate” outcome compared to the pure EOS
samples. Consequently, the percentage of patients with a
poor outcome was smaller in the MIX samples than in
the EOS samples. All effect sizes were moderate.
Effects of drop-out rates in the samples
Dropout rates in 17 studies ranged between a minimum
of 0% and a maximum of 59%. This distribution was
dichotomized at the median, and studies were classified
as having a high (>28%) or a low (<28%) dropout rate.
The effect of the attrition on the three outcome para-
meters was assessed by Mann Whitney tests and showed
highly significant differences in the “moderate” and
“poor” outcome groups but not in the “good” outcome
groups (see Table 3). The rate of “moderate” outcomes
was significantly higher in the low attrition samples
compared to the high attrition samples, whereas the op-
posite was the case in the “poor” outcome group with a
higher rate of poor outcomes in the high attrition sam-
ples; however, the effect sizes were small. In contrast,
the three studies with a dropout rate of 0% all experi-
enced high numbers of “poor” outcome [6,23,55], ran-
ging from 60.5% to 79%.
Table 4 Outcome by measures of functioning based on 21 studies (N=716)
Outcome variable Percentages of subjects by measures of functioning
GFS SSF Analysis
Mean SD Median Mean Rank Mean SD Median Mean Rank U z p rho
EOS N=222 N=200
Good 14.3 7.8 15.8 185.75 16.6 7.5 20.7 240.07 16486 −4.60 <.001 0.22
Moderate 27.0 12.8 28.0 220.02 21.7 12.8 17.0 202.05 20309 −1.52 n.s. 0.07
Poor 58.7 15.3 44.0 186.00 61.7 15.3 62.3 239.80 16540 −4.56 <.001 0.22
MIX N=128 N=166
Good 15.0 11.1 21.0 122.18 23.1 0.4 20.0 167.02 7383 −4.54 <.001 0.22
Moderate 30.5 12.1 28.0 131.75 36.0 1.0 44.0 159.64 8606 −2.82 .005 0.14
Poor 54.5 22.6 51.0 165.75 40.9 0.7 30.0 133.42 8287 −3.27 .001 0.16
Table 5 Outcome by duration of follow-up based on 21 studies (N= 716)
Outcome variable Percentages of subjects by duration of follow-up
<10 yrs >10 yrs Analysis
Mean SD Median Mean Rank Mean SD Median Mean Rank U z p rho
EOS N=187 N=235
Good 19.2 5.9 19.8 269.28 12.4 7.6 12.0 165.52 11167.5 −8.74 <.001 0.43
Moderate 29.4 14.8 38.2 243.08 20.6 13.3 23.7 186.37 16067.0 −4.78 <.001 0.23
Poor 51.4 15.8 42.0 150.18 67.0 18.4 60.5 260.30 10505.5 −9.28 <.001 0.45
MIX N=80 N=214
Good 16.4 11.6 16.0 120.69 20.8 7.7 21.0 157.51 6415.0 −3.35 .001 0.20
Moderate 37.5 11.7 37.0 180.86 32.1 13.0 28.0 135.03 5891.0 −4.16 <.001 0.24
Poor 46.1 23.5 47.0 126.55 47.1 15.3 51.0 155.33 6884.0 −2.61 .009 0.15
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Effects of the measures of functioning
In order to assess the effect of measures of functioning,
studies based on GFS were compared to those using SSF
measures. As shown in Table 4, there were highly signifi-
cant differences in the outcomes based on these two
measures of functioning in the “good” and “poor” out-
come groups of the EOS samples and the MIX samples.
In the latter sample, the outcome also differed signifi-
cantly for the “moderate” outcome group. In the EOS
samples, there were lower rates of “good” and “poor”
outcomes in studies based on GFS compared to SSF out-
comes. This was also true for the “moderate” outcome
groups of the MIX samples. The effect sizes were small
for all comparisons. In the 5 studies reporting a mean
GFS in EOS patients at follow up based on a total of 199
patients [5,39,50,51,53], the grand mean weighted for
sample sizes of these studies was 47.0.
Effects of duration of follow-up
Findings that deal with the effect of duration of follow-
up are presented in Table 5. In the EOS samples, the ef-
fect was highly significant for all three outcome groups.
Moreover, there was a moderate effect size indicating
that follow-up longer than 10 years was associated with
a smaller proportion of patients with a “good” and
“moderate” outcome and a larger proportion of patients
with a “poor” outcome. In the MIX samples, differences
for “good” and “moderate” outcomes were highly signifi-
cant, and differences were significant for poor outcomes;
however, the effect sizes were small. In these samples,
the rate of both “good” and “poor” outcomes was in-
creasing with longer follow-up periods, whereas the rate
of “moderate” outcome was declining.
Sex effects
Direct calculations could only be made on the basis of five
studies reporting separate results for males and females (4
with MIX and 1 with EOS patients). As Table 6 shows,
highly significant differences were found for “good,” “mod-
erate,” and “poor” outcome. These results indicate a gen-
erally less favourable outcome for males who less
frequently than females experienced a “good” or “moder-
ate” outcome and more frequently experienced a “poor”
outcome. The effect sizes were small to moderate.
To further investigate the effect of sex in a larger sam-
ple, we compared 6 studies with <50% males to 14 stud-
ies with >50% males; findings are shown in Table 7.
Differences were significant to highly significant on the
various levels of outcome. There is a clear indication that
both EOS and MIX studies containing a majority of
males generally experienced a less favourable outcome.
The proportion of “good” and “moderate” outcomes was
lower in studies based on a male predominance, whereas
the proportion was higher in the “poor” outcome groups.
Effects of time period of diagnosis
The data-set allowed a dichotomization into two groups
of studies, namely, those including patients diagnosed
Table 6 Outcome by sex based on 5 studies (N=190)
Outcome variable Percentages of subjects by sex
Males Females Analysis
Mean SD Median Mean Rank Mean SD Median Mean Rank U z p rho
N=92 N=98
Good 17.6 10.6 24.0 82.41 23.2 11.7 30.4 107.79 3304.0 −3.22 <.001 0.23
Moderate 23.2 19.3 25.0 68.80 37.3 37.3 46.0 120.56 2052.0 −6.56 <.001 0.48
Poor 59.2 23.2 74.0 107.78 39.5 39.5 36.0 83.97 3378. −3.03 .002 0.22
Table 7 Outcome by sex proportions based on 20 studies (N= 707)
Outcome variable Percentages of subjects
<50% males >50% males Analysis
Mean SD Median Mean Rank Mean SD Median Mean Rank U z p rho
EOS N=97 N=316
Good 19.4 5.3 15.8 262.34 13.9 7.9 13.0 190.01 9958 −5.26 <.001 0.26
Moderate 29.9 12.9 25.0 238.20 23.6 14.4 17.0 197.42 12300 −2.97 .003 0.15
Poor 50.7 11.0 50.0 175.80 62.5 19.9 62.3 216.58 12300 −2.96 .003 0.15
MIX N=157 N=137
Good 25.0 4.3 27.0 188.68 13.3 9.2 16.0 100.31 4290 −8.99 <.001 0.52
Moderate 36.1 13.1 44.0 160.27 30.7 12.1 28.0 132.86 8749 −2.79 .005 0.16
Poor 38.9 10.7 36.0 119.96 56.0 19.9 51.0 179.07 6340 −6.02 <.001 0.35
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before and after 1970 and those where all patients in the
sample were diagnosed in 1970 or later. Table 8 provides
a comparison of the outcome of these two groups. In
the EOS samples, there is a highly significant decline of
“good” outcomes in all patients diagnosed in or after
1970; however, the effect is only small. In contrast, there
are large effects indicating that the proportion of “mod-
erate” outcomes increased significantly, and the propor-
tion of “poor” outcomes decreased significantly over
time. Taking all three levels into account, the overall
outcome improved significantly over time.
There was only one MIX study containing patients
diagnosed before 1970. On the other hand, there were
clear moderate time period effects indicating highly sig-
nificant improvements with increasing proportions of
“good” and “moderate” outcomes and decreasing pro-
portions of “poor” outcomes.
Discussion
This is the first systematic review on the outcome of
EOS that is covering all suitable studies published in the
English-language literature since 1980. The analyses
were based on statistical tests measuring both the gen-
eral outcome and the effects of clearly defined predic-
tors. The review focuses on general trends; one has to
consider that the studies report rather diverse findings,
though in part, this diversity may be explained by the
pronounced heterogeneity of the schizophrenia syn-
drome itself [61,62]. Furthermore, the distributions of
the main outcome variables of “good,” “moderate,” and
“poor” differ depending on the measurements and defi-
nitions used in the various studies.
The main findings are the following: (a) the outcome
for EOS is relatively poor and less favourable than in
MIX samples; (b) samples with high dropout rates report
less “moderate” and more “poor” outcomes, even though
the effect sizes are small; (c) the effect sizes of measures
of functioning are also small, which can be attributed to
the fact that in EOS samples global measures of func-
tioning are associated with less “good” and “poor” out-
comes than specific measures of functioning; however,
in the MIX samples, specific measures of functioning
are associated with better outcomes on all three levels;
(d) in EOS, the effect of duration of follow-up shows less
favourable outcomes after more than 10 years of follow-
up, whereas in MIX samples, the longer follow-up is
associated with more “good,” less “moderate,” and more
“poor” outcomes; (e) the outcome in both EOS and MIX
samples is less favourable in males; and (f ) the outcome
is better in patients who had been diagnosed in more re-
cent decades. In the subsequent paragraphs, these major
findings will be put into perspective.
General outcome
In the current review, we discovered that 15.4% of EOS
patients experienced a “good” outcome, 24.5% experi-
enced a “moderate” outcome, and 60.1% experienced a
“poor” outcome. Clearly, these findings indicate that
EOS is still a mental illness with a rather unfavourable
prognosis; this conclusion is in accordance with previous
reviews [5,7,12,21,31,63,64]. On the other hand, these
previous reviews were based on non-aggregated data,
and they did not employ rigorous data analyses as the
authors do in the current review.
Furthermore, from the current analyses, it became evi-
dent that studies of patients with EOS show a worse
prognosis than studies containing both patients with
EOS and patients with other psychotic disorders (MIX).
Unfortunately, separate analyses of the outcome of the
various psychotic disorders were not feasible. In
addition, differences in time points of measurement in
the two samples may have been operant. Nevertheless,
the different outcome in the two groups may serve as
some indirect evidence that other psychotic disorders, i.
e., schizoaffective disorders, schizophreniform or bipolar
disorders with psychotic features, take a less serious
Table 8 Outcome by time period of diagnosis (N=705)
Outcome variable Percentages of subjects by period of diagnosis
<1970+ ≥1970 Analysis
Mean SD Median Mean Rank Mean SD Median Mean Rank U z p rho
EOS N=216 N=195
Good 16.2 7.6 15.8 228.03 15.8 7.1 19.8 181.60 16302.0 −3.987 <0.001 0.19
Moderate 17.2 7.3 17.0 137.25 24.9 15.8 38.2 282.15 6210.0 −12.452 <0.001 0.61
Poor 66.6 12.9 62.3 274.75 59.3 20.3 44.0 129.85 6210.0 −12.447 <0.001 0.61
MIX N=28 N=266
Good 3.6 0.0 3.6 38.50 19.6 7.9 21.0 158.97 672.0 −7.220 <0.001 0.42
Moderate 17.9 0.0 17.9 14.50 33.6 12.5 37.0 161.50 .0 −8.810 <0.001 0.51
Poor 78.5 0.0 78.5 256.50 46.8 15.3 47.0 133.03 672.0 −7.220 <0.001 0.42
Note: <1970+: studies including patients diagnosed before and after 1970.
≥1970: Studies containing patients diagnosed in 1970 and later.
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course in terms of chronicity and functioning because all
analyses based on the mixed psychotic samples showed
a less severe outcome than the pure EOS samples. This
finding is in accordance with similar studies in adults
[2,65].
When considering the impact of dropout rates, the
general findings on outcome may be only slightly differ-
ent than one would expect without any attrition in the
samples. In samples with high attrition rates, patients
with a “moderate” course of the disorder were less likely
to be followed up, and those with a “poor” outcome
were more likely to show up at follow-up assessments at
the various sites, whereas there was no attrition effect
on the rate of “good” outcomes. In contrast, it is unclear
whether the rate of “poor” outcomes would be different.
On the one hand, our analyses showed that the rate of
“poor” outcomes declined significantly with low attrition
rates. On the other hand, three studies without any attri-
tion showed an increased rate of “poor” outcomes. How-
ever, one has to keep in mind that the effect sizes for
attrition were only small. High dropout rates are very
common in psychiatric services with estimated rates ran-
ging from 20 to 60% [66], which proves to be in line
with the findings in the current review with dropout
rates between 0 and 59% and a median of 29%.
Impact of age at onset
In contrast to EOS, the outcome in studies of adult
patients is generally more favourable [5]. Hegarty et al.
[67] reviewed 320 adult studies from 1895 to 1992 (more
than 50,000 patients in total) and found that approxi-
mately 40% improved considerably during follow-up.
Jobe & Harrow [2] reviewed nine North American stud-
ies and the WHO-coordinated International Study of
Schizophrenia (ISoS), all with a follow-up period of
10 years or longer, and concluded that, although adult
patients with schizophrenia as a group have a worse out-
come than other psychiatric patients, only a few patients
show a progressive deteriorating course; depending on
the strictness of the criteria used for diagnosis, 21-57%
experience a “good” outcome. The ISoS compared long-
term follow-up studies (10–15 years) from 14 culturally
diversely treated incidence cohorts and four prevalence
cohorts, totaling 1633 subjects, and found that approxi-
mately 50% experience a “good” outcome [65].
A recent international study that examined outcome
after three years of follow-up in adult outpatient schizo-
phrenia (N = 11.078 from 37 countries) found that 66%
achieved clinical remission measured with the CGI,
whereas only 25.4% achieved functional remission
defined as good social functioning for 6 months in terms
of occupational/vocational status, independent living
and active social interactions [68]. There were large re-
gional differences in the study. Patients in Europe were
less likely to achieve clinical remission but were doing
better in regards to functional remission. The general
outcome both in the EOS group and the mixed psych-
otic group in the current review clearly shows that
schizophrenia and psychosis originating in childhood
and adolescence on average follows a worse course than
AOS. In comparison to other disorders originating in
childhood or adolescence, EOS stands out by way of its
particularly poor course. For instance, the outcome seen
with eating disorders is much better as is shown by simi-
lar types of analyses by the senior author [69,70].
This conclusion is also supported by a recent large co-
hort study from Israel with 12.071 participants. This
study found that earlier onset corresponds linearly with
the severity of the course of the disorder and appears to
have some prognostic impact [71]. Young age at onset
might have a detrimental effect on outcome because of
impact at very crucial times of development and neuro-
biological maturation in childhood and adolescence,
which prove to have more lasting effects in terms of both
cognitive and psychosocial impairments [1,32,35,72].
So far, unfortunately, there are only a small number of
outcome studies based on VEOS patients only, with an
over-representation of females, whereas there are more
studies with a varying range of age at onset within the
defined EOS age range. Furthermore, there is not a sin-
gle study based exclusively on patients with adolescent
onset schizophrenia; thus, there are no real solid data
for a comparison of the outcome of VEOS. Clearly, more
detailed analyses will be needed. Given the low preva-
lence rates of VEOS, only collaborative studies across
several sites could arrive at sample sizes needed for a
differential look at the effects of age, sex, clinical fea-
tures, or treatment effects on the outcome of VEOS.
The impact of the measures of functioning
The current study is the first to make use of analyzing
the impact of specific measures of functioning. Not sur-
prisingly, the advent of global measures of functioning
since the seventies also had an effect on the studies of
the outcome of EOS. In contrast, a few studies contin-
ued with an older tradition to define study-specific func-
tioning outcomes. Thus, a comparison of these two
different traditions became possible. In the pure EOS
studies, there were relatively small effect sizes, indicating
that studies based on the more recent GFS arrived at
slightly lower rates of both “good” and “poor” outcomes
and no differentiation in the “moderate” outcomes than
studies based on SSF outcomes. Accordingly, in EOS the
overall pattern is clearly not more favourable for one of
these two types of outcome. In the MIX studies, the
effects were also small though more clearly showing a
general pattern of less favourable outcomes based on
GFS rather than on SSF assessments. Thus, the two
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analyses point to different findings in the two types of
studies. In other words, the heterogeneity of the MIX
samples favour the SFS outcomes in which the measure-
ment might have tipped closer to the differences in the
diagnostic composition of the samples.
However, this interpretation is only an assumption that
needs further examination. Particularly, both the validity
and the reliability of these measures need to be studied
in greater detail. So far, this has been tested only in parts
for some of the GFS measures in general child and ado-
lescent psychiatry patients [73] but not specifically in
patients suffering from schizophrenia. In particular, the
GAF confounds symptoms and functioning with lower
ratings driven by symptoms, so someone who is symp-
tomatic but functional will receive a misleadingly low
rating.
The impact of intervention
In general, there is very little information on the impact
of intervention on the outcome in EOS, even though all
patient samples were seen clinically and received treat-
ment. With the exception of a single study [72], all stud-
ies provided treatment as usual. In a recent intervention
study with follow-up based on the Australian Early
Psychosis Prevention and Intervention Centre (EPPIC)
study, the authors found an increase in GAF score with
a mean GAF score of 64 at follow-up [42]. By compari-
son, Oie et al. [74] found a mean GAS score of 47.7 in
their EOS group containing 15 patients assessed when
they were clinically stable on antipsychotic medication
and followed up for 13 years. Moreover, Kao et al. [75]
found a mean GAF score of 47 in 19 EOS patients after
1 year follow-up, and Gochman et al. [76] found a mean
CGAS score of 43.6 after at least 8 years of follow-up.
In the single intervention study included in the current
review, the mean GAF score was 35 in the interven-
tion group and 24 in the control group [55]. Only
Ledda et al. [53] found a mean CGAS score of 62.1,
which is quite comparable to the finding of the EPPIC
study [42].
Nevertheless, in the latter study [42], the attrition rate
was large (22/63) in the total EOS group and well
explained only in a single person who committed sui-
cide. It is unclear whether the 21 other patients that
were not followed-up represent a subgroup with less
favourable outcome because the authors did not provide
a thorough attrition analysis. Thus, the claim of the
authors that their outcome findings are superior to pre-
vious outcomes is not yet substantiated.
The impact of duration of follow-up
The current analyses revealed, with small to moderate ef-
fect sizes, that across the three levels, the outcome dete-
riorated with longer follow-up periods (>10 years) in the
EOS samples, but the association was rather curvilinear
in the MIX samples with both “good” and “poor” out-
comes increasing at the expense of “moderate” outcomes
with longer follow-up periods. These differences again
point to the already noted different course of the other
psychoses, apart from schizophrenia. Nevertheless, the
present findings need to be interpreted with caution be-
cause the two follow-up periods of ≤10 and >10 years are
rather broad and reflect limitations of the data not allow-
ing a more fine-grained analysis. Furthermore, the ana-
lysis was based on a series of cross-sectional rather than
longitudinal studies. Unfortunately, among the 21 out-
come studies of the present analysis, there are only six
samples that were assessed repeatedly for follow-up and
were described in 9 articles [8,11,29,35,41,53,54,59,60].
The study by Krausz and Müller-Thomsen [11] showed
an increase in the proportion of “good” outcome from
the first follow-up at 5 years to the second follow-up at
11 years (19 to 31%), whereas the rate of “poor” out-
comes declined (74 to 59%) with a rather constant pro-
portion of “moderate” outcomes (7 to 10%). These
findings are in contrast to the findings of the current re-
view. Lay et al. [41]) studied a mixed psychotic group
that had been previously followed-up [35]. Unfortunately,
approximately one third of the group had dropped out in
between the two assessments, so it is unclear whether or
not the slight shift from “moderate” to “poor” outcome
(from 32 to 36%) is a valid finding. None of these longitu-
dinal studies made use of inferential statistical tests of
any significant change of the course of the disorder over
time.
The impact of sex
The current review supports the notion that male sex
carries a less favourable prognosis in EOS but also in
MIX samples. Nevertheless, as described in the methods
section, there were profound limitations in the data for a
proper analysis of sex effects. With a few exceptions
[1,11,41,52,55], the vast majority of studies did not strat-
ify outcome by sex; thus, two rather restricted types of
analyses had to be performed. The direct comparisons of
a small subsample suitable for direct comparisons clearly
favoured females in terms of having a better outcome.
The supplementary analysis based on a larger sample
compared the outcomes of samples with either less or
more than half of the samples being comprised of males.
The findings were in line with the previous results indi-
cating that male sex is a negative prognostic factor.
When looking at the various studies considered in the
current review, one may see that some studies reported
a tendency for worse outcome for males [1,5,6,8,11,15],
but only two of these provided statistically significant
differences [5,8]. One study found a specific “poor” out-
come in females which proved to be not statistically
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significant [49]. In contrast, most of the 20 studies either
reported no prognostic impact of sex [39,40] or did not
specify or mention sex in relation to outcome measures
[18,23,29,32,38,41,51,53,54]. One study noted that the risk
of suicide was increased about 30 times in males [50].
In the 21 studies listing the distribution of sex, the
average proportion of males was only 55%, a surprising
discovery given that schizophrenia usually has an earlier
onset among males than among females [17] and that
late onset after age 45 is more common among females
[24]. Especially with regard to VEOS onset, the literature
points to a male predominance [12] with a ratio of ap-
proximately 2–2.5:1 [17,24,64]; however, in the two stud-
ies of VEOS, female sex was dominant in both series of
patients [23,29]. In conclusion, there is some indication
of a potential sex bias in the outcome studies in terms of
containing more females than expected. Potential expla-
nations include a higher dropout rate of males from out-
come assessments due to less compliance and/or a
higher mortality rate.
The impact of time period of diagnosis
The time span of the original diagnosis of the patients
varied enormously between 1920 and 2010. During this
period, major changes in the understanding of schizo-
phrenia including the nosological classification, assess-
ment, and intervention took place. Thus, our analysis
took potential time period effects into account. The
data-set was dichotomized into studies containing
patients diagnosed before or after 1970 and patients all
diagnosed in 1970 or later. This grouping was not ideal
because it was still based on considerable heterogeneity
in terms of the time when the patients were diagnosed.
Nevertheless, it represented a feasible and pragmatic ap-
proach and reflected the fact that some major changes
in the classification of schizophrenia both in the ICD
and the DSM took place in the seventies.
The findings indicated that the overall outcome in
EOS and even more clearly in MIX samples improved
over time; thus, one may argue that the progress in
treatment and rehabilitation of schizophrenia might have
had a beneficial effect for those who were born and diag-
nosed later. In summary, one may also conclude that the
overall relatively poor long-term outcome of EOS is, in
part, due to the inclusion of studies containing patients
who had been diagnosed many decades ago.
Limitations
First, we decided to include only studies published after
1980, assuming that these studies would reflect a rather
common international frame of understanding of the
nosology of schizophrenia and psychoses. Even with this
restriction, though, there was a large time span over
which patients had been diagnosed. Even more
importantly, there may have been general problems with
the recruitments of the samples. There might have been
a bias both at the time of the first clinical presentation
and of follow-up assessments. The less severely affected
patients with a rapid remission of symptoms may not
have been included at the beginning of the studies. Fur-
thermore, it is not fully clear which effect no attrition
might have had in particular on the rate of “poor”
outcomes.
In the current review, we have used the categories of
“good,” “moderate,” and “poor” outcome. These categor-
ies are commonly used in the outcome literature of vari-
ous mental disorders. While the three authors of the
current review showed excellent convergence in the out-
come ratings of the various studies regarding this classi-
fication, one may argue that the cut-offs of these three
outcome groups are debatable. Nevertheless, our cut-offs
(>70 = good, 51–70 =moderate, and <50 = poor) imply
some face validity because they are clearly demarcating
major thresholds in functioning on GFS measures. Six
GFS studies were based exactly on these definitions,
whereas five studies used slightly different definitions.
Two studies [40,51] used a lower cut-off of >60 rather
than >70 for the definition of “good” outcomes, whereas
three studies [5,23,52] requested a lower cut-off of <40
for “poor” outcomes. Thus, these differences imply a less
strict definition of the outcome, so our findings might
have been slightly better if we had accepted these defini-
tions. Even among these five studies, though, there is no
fully congruent set of definitions. Thus, our procedure
was not only plausible in terms of the construction of
the various GFS measures but also served as a good
compromise considering the heterogeneity of definitions
of “good,” “moderate,” and “poor” outcomes.
Some of the limitations in reviews of schizophrenia, as
stated by Jobe & Harrow [2] and Castle and Morgan
[77], are also relevant for the current analyses. The com-
parability of follow-up studies is compromised by differ-
ing criteria for diagnosis and outcome variables, sample
selection (i.e., bias between inpatient and outpatient
indexing), varying duration of follow-up, differences in
the American and European tradition of diagnostic
approaches, and prospective and retrospective designs
leading to different preciseness of data acquisition. Fur-
thermore, many studies have used different assessments
for diagnosis and outcome. Various studies have lost
patients due to suicide, which were counted as drop-
outs; however, one could argue that suicide in terms of
outcome should be listed in the “poor” outcome group,
as suggested by Jarbin [50].
Furthermore, the lack of any clear data on mortality
rates in EOS and VEOS is a shortcoming of outcome
studies that should be addressed in future studies. Since
EOS and VEOS are very rare, patients often come from
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a large geographic area to the specialist research units;
thus, some patients travel far to be part of the study.
This might be a bias in terms of only the most affected
individuals will travel this far to be part of a study, which
also indicates that the patients who have the best out-
come might drop out.
Finally, no firm conclusions can be made thus far as to
the effects of interventions, and it is unclear whether the
large variation is due to different interventions, varying
clinical manifestations, or an interaction of both. As
with the study of other disorders, research on the effects
of intervention on course and outcome is most
neglected. Further studies are clearly needed.
Conclusions
This exhaustive analysis of the available evidence on the
outcome of EOS and VEOS points to the still rather
poor prognosis of early manifestations of schizophrenia.
The outcome of schizophrenia is worse than for other
psychotic disorders, which applies to both adult and
early onset schizophrenia. In both AOS and in EOS,
though, there are many individual differences and so the
course and outcome of schizophrenia is rather heteroge-
neous. Further insight into the long-term course of EOS
might result from refinements in the design of future
studies. Most particularly, the course of the individual
patient will ultimately profit from a better understanding
of the causes and refined treatment of this serious
disorder.
Future studies on the long-term outcome of EOS
might benefit from the following: (a) commonly used
diagnostic criteria and standardized assessments; (b)
detailed description of sample characteristics; (c) low at-
trition rates of the sample; (d) repeated and long-term
follow-up assessments with standardized instruments
covering clinical symptoms and functioning; (e) detailed
information on type and duration of interventions in-
cluding their effects on outcome; and (f ) the use of large
aggregated samples. These samples might be identified
in national registers so that a potential sample bias
caused by local hospital recruitment might be avoided.
Abbreviations
EOS: Early onset schizophrenia; VEOS: Very early onset schizophrenia;
AOS: Adult onset schizophrenia; MIX: Studies including both EOS and other
psychotic disorders; GFS: General functioning scale; SSF: Study-specific
functioning; GAF: Global assessment of functioning; CGAS: Children’s global
assessment scale; GAS: Global assessment scale.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LC carried out all statistical analyses, DL was responsible for the literature
search, HCS was responsible for the design of the study. All three authors
performed the ratings of the outcomes and contributed equally to the
writing of the manuscript. All authors read and approved the final
manuscript.
Authors' information
Both LC and DL are psychologists and are currently working on dissertation
projects dealing with various clinical aspects of early onset schizophrenia.
Both are specializing in clinical child and adolescent psychology within child
and adolescent psychiatry departments in Denmark. HCS is a research
professor in child and adolescent psychiatry, a professor emeritus in child
and adolescent psychiatry, and an honorary professor in clinical child and
adolescent psychology.
Sources of funding
None of the authors received any funding for this study.
Author details
1Research Unit at Glostrup Center of Child and Adolescent Psychiatry, Ndr.
Ringvej 69, 2600, Glostrup, Denmark. 2Present address: Research Unit for
Child and Adolescent Psychiatry, Aalborg Psychiatric Hospital, Aarhus
University Hospital, Moelleparkvej 10, Aalborg, DK 9000, Denmark. 3Clinical
Psychology and Epidemiology, Institute of Psychology, University of Basel,
Missionsstrasse 60/62, Basel, CH 4055, Switzerland. 4Department of Child and
Adolescent Psychiatry, University of Zurich, Neptunstrasse 60, Zürich H-8032,
Switzerland.
Received: 5 April 2012 Accepted: 10 September 2012
Published: 19 September 2012
References
1. Helgeland MI, Torgersen S: Stability and prediction of schizophrenia from
adolescence to adulthood. Eur Child Adolesc Psychiatry 2005, 14:83–94.
2. Jobe TH, Harrow M: Long-term outcome of patients with schizophrenia: a
review. Can J Psychiatry 2005, 50:892–900.
3. American Academy of Child and Adolescent Psychiatry: Practice parameter
for the assessment and treatment of children and adolescents with
schizophrenia. American Academy of Child and Adolescent Psychiatry.
J Am Acad Child Adolesc Psychiatry 2001, 40:4S–23S.
4. Basso MR, Nasrallah HA, Olson SC, Bornstein RA: Cognitive deficits
distinguish patients with adolescent- and adult-onset schizophrenia.
Neuropsychiatry Neuropsychol Behav Neurol 1997, 10:107–112.
5. Fleischhaker C, Schulz E, Tepper K, Martin M, Hennighausen K, Remschmidt
H: Long-term course of adolescent schizophrenia. Schizophr Bull 2005,
31:769–780.
6. Gillberg IC, Hellgren L, Gillberg C: Psychotic disorders diagnosed in
adolescence. Outcome at age 30 years. J Child Psychol Psychiatry 1993,
34:1173–1185.
7. Hollis C: Adolescent schizophrenia. Adv Psychiatr Treat 2000, 6:83–92.
8. Inoue K, Nakajima T, Kato N: A longitudinal study of schizophrenia in
adolescence.I. The one- to three-year outcome. Jpn J Psychiatry Neurol
1986, 40:143–151.
9. Kim Y, Kim BN, Cho SC, Kim JW, Shin MS: Long-term sustained benefits of
clozapine treatment in refractory early onset schizophrenia: a
retrospective study in Korean children and adolescents. Hum
Psychopharmacol 2008, 23:715–722.
10. Kimura S, Asai S, Wakeno M, Aoki N: On early and mid-adolescent
schizophrenia. Part 1: Phenomenological aspects. Folia Psychiatr Neurol
Jpn 1978, 32:41–56.
11. Krausz M, Muller-Thomsen T: Schizophrenia with onset in adolescence: an
11-year followup. Schizophr Bull 1993, 19:831–841.
12. Kyriakopoulos M, Frangou S: Pathophysiology of early onset
schizophrenia. Int Rev Psychiatry 2007, 19:315–324.
13. Mattai AK, Hill JL, Lenroot RK: Treatment of early-onset schizophrenia. Curr
Opin Psychiatry 2010, 23:304–310.
14. McKenna K, Gordon CT, Rapoport JL: Childhood-onset schizophrenia:
Timely neurobiological research. J Am Acad Child Adolesc Psychiatry 1994,
33:771–781.
15. Reichert A, Kreiker S, Mehler-Wex C, Warnke A: The psychopathological
and psychosocial outcome of early-onset schizophrenia: preliminary data
of a 13-year follow-up. Child Adolesc Psychiatry Ment Health 2008, 2:6.
16. Vyas NS, Hadjulis M, Vourdas A, Byrne P, Frangou S: The Maudsley early
onset schizophrenia study. Predictors of psychosocial outcome at 4-year
follow-up. Eur Child Adolesc Psychiatry 2007, 16:465–470.
17. Werry JS: Child and adolescent (early onset) schizophrenia: a review in
light of DSM-III-R. J Autism Dev Disord 1992, 22:601–624.
Clemmensen et al. BMC Psychiatry 2012, 12:150 Page 14 of 16
http://www.biomedcentral.com/1471-244X/12/150
18. Werry JS, McClellan JM, Andrews LK, Ham M: Clinical features and
outcome of child and adolescent schizophrenia. Schizophr Bull 1994,
20:619–630.
19. American Psychiatric Association: Diagnostic and statistical manual of mental
disorders. 4th edition. Washington, DC: American Psychiatric Association;
1994.
20. Eggers C, Bunk D, Volberg G, Ropcke B: The ESSEN study of childhood-
onset schizophrenia: selected results. Eur Child Adolesc Psychiatry 1999,
8:21–28.
21. Gonthier M, Lyon MA: Childhood-Onset Schizophrenia: An Overview.
[References]. Psychol Sch 2004, 41:803–811.
22. Hollis C: Child and adolescent (juvenile onset) schizophrenia. A case
control study of premorbid developmental impairments. Br J Psychiatry
1995, 166:489–495.
23. Remschmidt H, Martin M, Fleischhaker C, Theisen FM, Hennighausen K,
Gutenbrunner C, Schulz E: Forty-two-years later: the outcome of
childhood-onset schizophrenia. J Neural Transm 2007, 114:505–512.
24. Russell AT: The clinical presentation of childhood-onset schizophrenia.
Schizophr Bull 1994, 20:631–646.
25. Schothorst PF, Emck C, Van EH: Characteristics of early psychosis. Compr
Psychiatry 2006, 47:438–442.
26. McKenna K, Gordon CT, Lenane M, Kaysen D, Fahey K, Rapoport JL: Looking
for childhood-onset schizophrenia: the first 71 cases screened. J Am Acad
Child Adolesc Psychiatry 1994, 33:636–644.
27. Cannon M, Jones P, Huttunen MO, Tanskanen A, Huttunen T, Rabe-Hesketh
S, Murray RM: School performance in Finnish children and later
development of schizophrenia: a population-based longitudinal study.
Arch Gen Psychiatry 1999, 56:457–463.
28. Kolvin I: Studies in the childhood psychoses. I. Diagnostic criteria and
classification. Br J Psychiatry 1971, 118:381–384.
29. Eggers C, Bunk D: The long-term course of childhood-onset
schizophrenia: a 42-year followup. Schizophr Bull 1997, 23:105–117.
30. Merry SN, Werry JS: Course and Prognosis. In Schizophrenia in children and
adolescents. Edited by Remschmidt H. Cambridge: Cambridge University
Press; 2001:268–298.
31. Asarnow JR, Tompson MC, McGrath EP: Annotation: childhood-onset
schizophrenia: clinical and treatment issues. J Child Psychol Psychiatry
2004, 45:180–194.
32. Aarkrog T: Psychotic adolescents 20–25 years later. Nord J Psychiatry 1999,
53(Suppl 42):i-36.
33. Fraguas D, de Castro MJ, Medina O, Parellada M, Moreno D, Graell M,
Merchan-Naranjo J, Arango C: Does diagnostic classification of early-onset
psychosis change over follow-up? Child Psychiatry Hum Dev 2008,
39:137–145.
34. Jarbin H, von Knorring AL: Diagnostic stability in adolescent onset
psychotic disorders. Eur Child Adolesc Psychiatry 2003, 12:15–22.
35. Schmidt M, Blanz B, Dippe A, Koppe T, Lay B: Course of patients diagnosed
as having schizophrenia during first episode occurring under age
18 years. Eur Arch Psychiatry Clin Neurosci 1995, 245:93–100.
36. Asarnow JR: Childhood-onset schizotypal disorder: a follow-up study and
comparison with childhood-onset schizophrenia. J Child Adolesc
Psychopharmacol 2005, 15:395–402.
37. Castro-Fornieles J, Baeza I, la SE D, Gonzalez-Pinto A, Parellada M, Graell M,
Moreno D, Otero S, Arango C: Two-year diagnostic stability in early-onset
first-episode psychosis. J Child Psychol Psychiatry 2011,
52:1089–1098.
38. Hollis C: Adult outcomes of child- and adolescent-onset schizophrenia:
diagnostic stability and predictive validity. Am J Psychiatry 2000,
157:1652–1659.
39. Maziade M, Gingras N, Rodrigue C, Bouchard S, Cardinal A, Gauthier B,
Tremblay G, Cote S, Fournier C, Boutin P, et al: Long-term stability of
diagnosis and symptom dimensions in a systematic sample of patients
with onset of schizophrenia in childhood and early adolescence. I:
nosology, sex and age of onset. Br J Psychiatry 1996, 169:361–370.
40. Röpcke B, Eggers C: Early-onset schizophrenia: a 15-year follow-up. Eur
Child Adolesc Psychiatry 2005, 14:341–350.
41. Lay B, Blanz B, Hartmann M, Schmidt MH: The psychosocial outcome of
adolescent-onset schizophrenia: a 12-year followup. Schizophr Bull 2000,
26:801–816.
42. Amminger GP, Henry LP, Harrigan SM, Harris MG, Varez-Jimenez M, Herrman
H, Jackson HJ, McGorry PD: Outcome in early-onset schizophrenia
revisited: Findings from the Early Psychosis Prevention and Intervention
Centre long-term follow-up study. Schizophr Res 2011, 131:112–119.
43. King LJ, Pittman GD: A follow-up of 65 adolescent schizophrenia patients.
Dis Nerv Syst 1971, 32:328–334.
44. Jansson B, Alstrom J: The relation between prognosis, symptoms and
background factors in suspected schizophrenic insufficiencies in young
people. Acta Psychiatr Scand Suppl 1967, 198:1–96.
45. Schimmelmann BG, Conus P, Cotton S, McGorry PD, Lambert M: Pre-
treatment, baseline, and outcome differences between early-onset and
adult-onset psychosis in an epidemiological cohort of 636 first-episode
patients. Schizophr Res 2007, 95:1–8.
46. Wiersma D, Wanderling J, Dragomirecka E, Ganev K, Harrison G, Der An HW,
Nienhuis FJ, Walsh D: Social disability in schizophrenia: its development
and prediction over 15 years in incidence cohorts in six European
centres. Psychol Med 2000, 30:1155–1167.
47. Carpenter WT Jr, Kirkpatrick B: The heterogeneity of the long-term course
of schizophrenia. Schizophr Bull 1988, 14:645–652.
48. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement 7. J Clin
Epidemiol 2009, 62:1006–1012.
49. Cawthron P, James A, Dell J, Seagroatt V: Adolescent onset psychosis. A
clinical and outcome study. J Child Psychol Psychiatry 1994,
35:1321–1332.
50. Jarbin H: Long-term Outcome, Suicidal behaviour, Quality of Life and Expressed
Emotion in Adolescent Onset Psychotic Disorders. 2003.
51. Asarnow JR, Tompson MC, Goldstein MJ: Childhood-onset schizophrenia: a
followup study. Schizophr Bull 1994, 20:599–617.
52. Hassan GA, Taha GR: Long term functioning in early onset psychosis: two
years prospective follow-up study. Behav Brain Funct 2011, 7:28.
53. Ledda MG, Fratta AL, Pintor M, Zuddas A, Cianchetti C: Early-onset
psychoses: comparison of clinical features and adult outcome in 3
diagnostic groups. Child Psychiatry Hum Dev 2009, 40:421–437.
54. McClellan JM, Werry JS: Schizophrenic psychosis. In Risks and outcomes in
developmental psychopathology. Edited by Steinhausen HC, Vehulst FC.
Oxford: Oxford University Press; 1999:267–282.
55. Rund BR: The relationship between psychosocial and cognitive
functioning in schizophrenic patients and expressed emotion and
communication deviance in their parents. Acta Psychiatr Scand 1994,
90:133–140.
56. Hall RC: Global assessment of functioning. A modified scale.
Psychosomatics 1995, 36:267–275.
57. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A
children's global assessment scale (CGAS). Arch Gen Psychiatry 1983,
40:1228–1231.
58. Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale. A
procedure for measuring overall severity of psychiatric disturbance. Arch
Gen Psychiatry 1976, 33:766–771.
59. Eggers C: Verlaufweisen kindlicher und präpuberaler Schizophrenien,
Monogrpahien aus dem Gesamtgebiete der Psychiatric, bd. 9. Berlin:
Springer; 1973.
60. Eggers C: Course and prognosis in childhood schizophrenia. J Autism
Child Schizophr 1978, 8:21–36.
61. Malla A, Payne J: First-episode psychosis: psychopathology, quality of life,
and functional outcome. Schizophr Bull 2005, 31:650–671.
62. Hollis C: Diagnosis and differential diagnosis. In Schizophrenia in children
and adolescents. Edited by Remschmidt H. Cambridge: Cambridge University
Press; 2001:82–119.
63. Masi G, Mucci M, Pari C: Children with schizophrenia: clinical picture and
pharmacological treatment. CNS Drugs 2006, 20:841–866.
64. Remschmidt HE, Schulz E, Martin M, Warnke A, Trott GE: Childhood-onset
schizophrenia: history of the concept and recent studies. Schizophr Bull
1994, 20:727–745.
65. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC,
Ganev K, Giel R, Der An HW, et al: Recovery from psychotic illness: a
15- and 25-year international follow-up study. Br J Psychiatry 2001,
178:506–517.
66. Reneses B, Munoz E, Lopez-Ibor JJ: Factors predicting drop-out in
community mental health centres 1. World Psychiatry 2009, 8:173–177.
67. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G: One hundred
years of schizophrenia: a meta-analysis of the outcome literature. Am J
Psychiatry 1994, 151:1409–1416.
Clemmensen et al. BMC Psychiatry 2012, 12:150 Page 15 of 16
http://www.biomedcentral.com/1471-244X/12/150
68. Haro JM, Novick D, Bertsch J, Karagianis J, Dossenbach M, Jones PB: Cross-
national clinical and functional remission rates: Worldwide
Schizophrenia Outpatient Health Outcomes (W-SOHO) study. Br J
Psychiatry 2011, 199:194–201.
69. Steinhausen HC, Weber S: The outcome of bulimia nervosa: findings from
one-quarter century of research. Am J Psychiatry 2009, 166:1331–1341.
70. Steinhausen HC: The outcome of anorexia nervosa in the 20th century.
Am J Psychiatry 2002, 159:1284–1293.
71. Rabinowitz J, Levine SZ, Hafner H: A population based elaboration of the
role of age of onset on the course of schizophrenia. Schizophr Res 2006,
88:96–101.
72. Mayoral M, Zabala A, Robles O, Bombin I, Andres P, Parellada M, Moreno D,
Graell M, Medina O, Arango C: Neuropsychological functioning in
adolescents with first episode psychosis: a two-year follow-up study. Eur
Psychiatry 2008, 23:375–383.
73. Dyrborg J, Larsen FW, Nielsen S, Byman J, Nielsen BB, Gautre-Delay F: The
Children's Global Assessment Scale (CGAS) and Global Assessment of
Psychosocial Disability (GAPD) in clinical practice–substance and
reliability as judged by intraclass correlations. Eur Child Adolesc Psychiatry
2000, 9:195–201.
74. Oie M, Sundet K, Ueland T: Neurocognition and functional outcome in
early-onset schizophrenia and attention-deficit/hyperactivity disorder: a
13-year follow-up. Neuropsychology 2011, 25:25–35.
75. Kao YC, Liu YP: Effects of age of onset on clinical characteristics in
schizophrenia spectrum disorders. BMC Psychiatry 2010, 10:63.
76. Gochman PA, Greenstein D, Sporn A, Gogtay N, Keller B, Shaw P, Rapoport
JL: IQ stabilization in childhood-onset schizophrenia. Schizophr Res 2005,
77:271–277.
77. Castle DJ, Morgan V: Epidemiology. In Clinical Handbook of Schizophrenia.
Edited by Mueser KT, Jeste DV. New York: The Guilford Press; 2008:14–24.
doi:10.1186/1471-244X-12-150
Cite this article as: Clemmensen et al.: A systematic review of the long-
term outcome of early onset schizophrenia. BMC Psychiatry 2012 12:150.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Clemmensen et al. BMC Psychiatry 2012, 12:150 Page 16 of 16
http://www.biomedcentral.com/1471-244X/12/150
